Routine first‐trimester combined screening for pre‐eclampsia: pregnancy‐associated plasma protein‐A or placental growth factor?
| Autor: | B. Thilaganathan, Aris T. Papageorghiou, Laure Noel, G. P. Guy, E. Buck, K. Forenc, S. Jones |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
medicine.medical_specialty Pregnancy-associated plasma protein A Gestational Age Risk Assessment Pre-Eclampsia Obstetrics and gynaecology Pregnancy Interquartile range Prenatal Diagnosis medicine.artery medicine Humans Pregnancy-Associated Plasma Protein-A Radiology Nuclear Medicine and imaging Uterine artery Placenta Growth Factor Retrospective Studies Eclampsia Radiological and Ultrasound Technology Obstetrics business.industry Infant Newborn Obstetrics and Gynecology General Medicine medicine.disease Pregnancy Trimester First Uterine Artery ROC Curve Reproductive Medicine Pulsatile Flow Infant Small for Gestational Age Small for gestational age Female Down Syndrome Nuchal Translucency Measurement business Trisomy Algorithms Biomarkers |
| Zdroj: | Ultrasound in Obstetrics & Gynecology. 58:540-545 |
| ISSN: | 1469-0705 0960-7692 |
| DOI: | 10.1002/uog.23669 |
| Popis: | OBJECTIVE To compare the screening performance of serum pregnancy-associated plasma protein-A (PAPP-A) vs placental growth factor (PlGF) in routine first-trimester combined screening for pre-eclampsia (PE), small-for-gestational age (SGA) at birth and trisomy 21. METHODS This was a retrospective study nested in pregnancy cohorts undergoing first-trimester combined screening for PE and trisomy 21 using The Fetal Medicine Foundation (FMF) algorithm based on maternal characteristics, nuchal translucency thickness, PAPP-A, free beta-human chorionic gonadotropin, blood pressure and uterine artery Doppler. Women at high risk for preterm PE (≥ 1 in 50) received 150 mg of aspirin per day, underwent serial fetal growth scans at 28 and 36 weeks and were offered elective birth from 40 weeks of gestation. PlGF was quantified retrospectively from stored surplus first-trimester serum samples. The performance of combined first-trimester screening for PE and SGA using maternal history, blood pressure, uterine artery pulsatility index and either PAPP-A or PlGF was calculated. Similarly, the performance of combined first-trimester screening for trisomy 21 was calculated using either PAPP-A or PlGF in addition to maternal age, nuchal translucency thickness and free beta-human chorionic gonadotropin. RESULTS Maternal serum PAPP-A was assayed in 1094 women, including 82 with PE, 111 with SGA (birth weight |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text